Invitae Akcie

Invitae EPS

Delisted·7. 8. 2024

Zisk na akcii (EPS) společnosti Invitae (NVTAQ) k datu 15. 8. 2026 je -5,23 USD. V předchozím roce byl Zisk na akcii (EPS) -12,73 USD — změna o -58,95 % (vyšší).

EPS

-5,23USD

YoY

-58,95%

Poslední aktualizace:

Zisk na akcii (EPS) společnosti Invitae je 2026 -5,23 USD. Zisk na akcii (EPS) společnosti Invitae byl 2025 -12,73 USD. Klesá tak o -58,95% vyšší než v předchozím roce.
Access this data via the Eulerpool API

Invitae Analýza akcií

Co dělá Invitae? Invitae Corp is a US-based company specialized in providing genetic tests for the diagnosis, treatment, and prevention of diseases. It was founded in 2010 and is headquartered in San Francisco, California. The company's goal is to lower the cost of genetic testing and increase accessibility for patients through automation and sample pooling methods. Invitae has received significant funding and has expanded its capital through multiple rounds of investments from venture capital firms, totaling nearly half a billion dollars. Its business model focuses on offering genetic tests to a wide range of patient groups, streamlining the testing processes through automation and software optimization. Invitae serves consumers directly, as well as medical professionals, hospitals, health centers, laboratories, and health insurance companies. The company aims to improve disease diagnosis and early detection while promoting long-term patient health. Invitae has broadened its capabilities through strategic acquisitions and partnerships, consolidating genetic data on a single platform. It offers a diverse portfolio of genetic tests for the diagnosis, treatment, and prevention of various diseases, including cancer predisposition, cardiovascular diseases, rare inherited diseases, neurological disorders, and medical genomics. The company also provides genetic counseling and family-oriented diagnosis services, along with an online platform facilitating interactive communication between doctors and patients, enabling the sharing and presentation of genetic information and test results. Invitae is an innovative company that has established itself as a market leader in genetic testing, offering a wide range of products and services facilitated by advanced technologies and data storage solutions. The recent acquisitions and partnerships have expanded Invitae's portfolio, improved its technology platform, and strengthened its position as a provider of high-quality healthcare services, enabling well-informed decision-making for patients and medical professionals. Invitae je jednou z nejoblíbenějších společností na Eulerpool.com.

Často kladené otázky ohledně akcií Invitae

Zisk na akcii (EPS) společnosti Invitae činí -5,23 USD v roce 2026.

Zisk na akcii (EPS) společnosti Invitae se změnilo z -12,73 USD na -5,23 USD, což představuje změnu o -58,95 %. Hodnota je vyšší než v předchozím roce.

Na Eulerpool najdete úplný historický vývoj Zisk na akcii (EPS) Invitae od roku 2006 – s ročními hodnotami, grafy a podrobnou analýzou.

Zisk na akcii měří část zisku společnosti připadající na každou vydanou akcii a je klíčovou metrikou pro hodnocení ziskovosti společnosti na základě akcie.

EPS = Čistý zisk / Počet vydaných akcií

Access this data via the Eulerpool API

Výkaz zisku a ztráty — Invitae

Všechny klíčové ukazatele — Invitae